Workflow
高纯及超高纯应用材料
icon
Search documents
【私募调研记录】明汯投资调研新莱应材、华润微
Zheng Quan Zhi Xing· 2025-05-01 00:09
调研纪要:华润微在汽车电子、新能源等领域成为重点发力及高增长领域。MOSFET预期增长15%, IGBT预期增长50%。2025年一季度毛利率下降1.1个百分点,主要因高端掩模工厂投产导致折旧增加及 IC类产品价格下降。模拟类产品接单情况良好,MEMS产品订单情况明显好转。2025年资本开支预计20 亿元,主要用于封测基地产能爬坡及设备投资。消费领域以降本增效为目标,汽车、工控领域以提高产 品可靠性为目标。重庆12吋产线产能利用率70%,深圳12吋产线处于产能爬坡阶段。汽车电子占比 21%,新能源占比20%,家电占比18%,工业设备占比16%,通讯设备占比9%。碳化硅产品系列不断丰 富,车规级SiC MOS和SiC模块在车企推进测试中。行业呈现温和复苏趋势,产品价格将稳定在一定区 间内。 机构简介: 调研纪要:新莱应材主营洁净应用材料和高纯及超高纯应用材料,2024年主营收入28.49亿元,同比增 长5.08%。受益于半导体国产化趋势,2024年营收增长5.08%,2025年Q1营收下降2.33%。公司泛半导体 产品涵盖真空和UHP应用,具有高真空度、优质材料和严格检测标准。半导体市场预计2024年达6112 ...
新莱应材(300260):点评:国内半导体行业需求强劲,看好零部件业务增长带动业绩修复
SINOLINK SECURITIES· 2025-04-29 13:48
Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5][12]. Core Insights - In 2024, the company achieved a revenue of 2.849 billion RMB, a year-on-year increase of 5.08%, but the net profit attributable to shareholders decreased by 4.05% to 226 million RMB [2]. - The semiconductor equipment market is expected to see strong demand, with projected net profits for 2025, 2026, and 2027 at 328 million RMB, 491 million RMB, and 669 million RMB respectively, reflecting growth rates of 44.77%, 49.78%, and 36.22% [5][9]. - The company is focusing on clean application materials and high-purity materials, with significant growth in the semiconductor sector, which saw a revenue increase of 29.9% in 2024 [4]. Summary by Sections Financial Performance - In Q1 2025, the company reported a slight revenue decline of 2.33% year-on-year, with a net profit decrease of 25.56% [2][3]. - The comprehensive gross margin for 2024 was 25.72%, while Q1 2025 saw a decline to 23.82% [3]. - The company’s revenue for 2024 was 2.849 billion RMB, with a projected revenue of 3.506 billion RMB for 2025, indicating a growth rate of 23.04% [9]. Market Outlook - The report highlights a strong demand for semiconductor equipment in China, which is expected to drive domestic production and market share recovery for the company [4][5]. - The food and pharmaceutical sectors are showing moderate recovery, with revenues of 1.680 billion RMB and 305 million RMB respectively in 2024 [4]. Valuation Metrics - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.80 RMB, 1.20 RMB, and 1.64 RMB respectively, with corresponding price-to-earnings (P/E) ratios of 39, 26, and 19 [5][9].